|
| Press Releases |
|
 |
|
| Thursday, July 20, 2023 |
|
|
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023（AAIC2023）において発表 |
| エーザイ株式会社とバイオジェン・インクは、このたび、アルツハイマー病（AD）治療剤レカネマブ（一般名、米国ブランド名：「LEQEMBI」）について、臨床第III相Clarity AD試験におけるレカネマブ投与によるアミロイドベータ（Aβ）の減少とパスウェイにおける下流のバイオマーカー変化の解析結果、ならびに現在開発中の皮下投与製剤に関する最新知見をアルツハイマー病協会国際会議2023において、発表したことをお知らせします。 more info >> |
|
|
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes. more info >> |
|
| Wednesday, July 12, 2023 |
|
|
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research |
| Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
| Friday, July 7, 2023 |
|
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
|
エーザイとバイオジェン・インク、「LEQEMBI(R)」（レカネマブ）がアルツハイマー病治療薬として米国FDAよりフル承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、米国食品医薬品局（FDA）が「LEQEMBI(R)」注射100 mg/mL溶液（一般名：レカネマブ）について、フル承認に向けた生物製剤承認一部変更申請（supplemental Biologics License Application：sBLA）を承認したことをお知らせします。 more info >> |
|
| Friday, June 30, 2023 |
|
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
| Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
| Thursday, June 29, 2023 |
|
|
エーザイ、Gates Ventures、Health Data Research UK、LifeArc、およびエジンバラ大学は認知症の課題解決に寄与するデジタル・ソリューション開発をめざす共同研究「NEURii」を開始 |
| エーザイ株式会社（本社：東京都）、Gates Ventures（米国、シアトル）、Health Data Research UK（英国、ロンドン、以下、HDR UK）、LifeArc（英国、ロンドン）、およびエジンバラ大学（英国、エジンバラ）は、このたび、2年間の新規共同研究契約を締結したことをお知らせします。 more info >> |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
|
エーザイ、東京都文京区の2023年度認知症検診事業において「のうKNOW(R)」による脳の健康度測定を継続実施 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、東京都文京区(以下、文京区)が実施する2023年度認知症検診事業（以下、本事業）において、当社の認知機能のデジタルチェックツール「のうKNOW(R)」による脳の健康度測定が継続実施されることをお知らせします。 more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
隨著歐洲與東南亞吸納越來越多國際護理人員，全球護理人員遷徙模式正發生轉變
Apr 28, 2026 22:00 HKT/SGT
|
|
|
随着欧洲和东南亚吸纳的国际护士比例不断上升，全球护士流动格局正在发生变化
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Tenstorrent、新たなネットワーク型AIアーキテクチャ上で展開される業界最高水準の性能により大規模AIを実現
Apr 28, 2026 22:00: JST
|
|
|
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture
Apr 28, 2026 21:00 HKT/SGT
|
|
|
TANAKA to Showcase Advanced Semiconductor Materials and Circular Economy Initiatives at SEMICON Southeast Asia 2026
Apr 28, 2026 21:00 JST
|
|
|
HKTDC's response to Hong Kong's export figures for March
Apr 28, 2026 19:23 HKT/SGT
|
|
|
CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion
Apr 28, 2026 19:11 HKT/SGT
|
|
|
康希諾生物一季度業績穩健增長 全生命週期佈局打開長期價值空間
Apr 28, 2026 19:04 HKT/SGT
|
|
|
Kincora Commences Drilling at the Historic Condobolin Mining Field
Apr 28, 2026 19:00 HKT/SGT
|
|
|
由美國馬球協會（U.S. Polo Assn.）與 ESPN 共同贊助的「美國公開馬球錦標賽(R)」決賽圓滿落幕，為本季創下多項紀錄的美國馬球賽季畫下句點
Apr 28, 2026 19:00 HKT/SGT
|
|
|
由美国马球协会（U.S. Polo Assn.）和ESPN联合呈现的著名美国公开马球锦标赛（U.S. Open Polo Championship(R)）决赛，为这个创下多项纪录的美国马球赛季画上了句号
Apr 28, 2026 19:00 HKT/SGT
|
|
|
The Prestigious U.S. Open Polo Championship(R) Final Closes a Record-Breaking American Polo Season, Supported by U.S. Polo Assn. and ESPN
Apr 28, 2026 19:00 HKT/SGT
|
|
|
康希诺生物一季度业绩稳健增长 全生命周期布局打开长期价值空间
Apr 28, 2026 18:58 HKT/SGT
|
|
|
NEC Launches "Africa Corporate Innovation Program" Accelerating Business Through Co-Creation with African Startups
Apr 28, 2026 19:05 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
